fluoxetine has been researched along with riluzole in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 12 (66.67) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Johnson, BM; Meanwell, NA; Shu, YZ; Zhuo, X | 1 |
| Borsotto, M; Devader, C; Gandin, C; Heurteaux, C; Labbal, F; Mazella, J; Moha ou Maati, H; Peyronnet, R; Veyssiere, J | 1 |
| Gu, JG; Ling, J; Viatchenko-Karpinski, V | 1 |
| Barkhof, F; Bastow, R; Braisher, M; Chandran, S; Chataway, J; Connick, P; Cranswick, G; De Angelis, F; Doshi, A; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hawkins, C; John, N; MacManus, D; Ourselin, S; Parker, RA; Pavitt, SH; Plantone, D; Prados Carrasco, F; Ross, M; Sharrack, B; Stallard, N; Stutters, J; Weir, CJ | 2 |
| Borsotto, M; Faucherre, A; Heurteaux, C; Jopling, C; Mazella, J; Moha Ou Maati, H; Nasr, N | 1 |
| Barkhof, F; Chataway, J; DeAngelis, F; Doshi, A; Gandini Wheeler-Kingshott, CAM; John, NA; MacManus, D; Marshall, I; Monteverdi, A; Parker, RA; Plantone, D; Prados, F; Schneider, T; Solanky, BS; Stutters, J; Weir, CJ | 1 |
| Chandran, S; Chataway, J; Connick, P; de Angelis, F; Foley, P; Parker, RA; Weir, CJ; Young, C | 1 |
2 review(s) available for fluoxetine and riluzole
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for fluoxetine and riluzole
| Article | Year |
|---|---|
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple scl
Topics: Adult; Amiloride; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Riluzole; Treatment Outcome | 2018 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Riluzole; Treatment Outcome | 2020 |
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Topics: Adult; Amiloride; Aspartic Acid; Biomarkers; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fluoxetine; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroimaging; Neuroprotective Agents; Proton Magnetic Resonance Spectroscopy; Protons; Riluzole | 2020 |
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuralgia; Riluzole | 2022 |
12 other study(ies) available for fluoxetine and riluzole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
Topics: Drug Design; Fluorine; Halogenation; Humans; Pharmaceutical Preparations | 2020 |
A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases.
Topics: Cell Hypoxia; Drug Discovery; Drug Evaluation, Preclinical; Fatty Acids, Unsaturated; Fluoxetine; Green Fluorescent Proteins; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Ion Channel Gating; Nervous System Diseases; Neuroprotective Agents; Patch-Clamp Techniques; Peptides; Potassium Channels, Tandem Pore Domain; Protein Transport; Receptors, Cell Surface; Riluzole; Stress, Mechanical | 2011 |
Characterization of temperature-sensitive leak K
Topics: Animals; Cell Size; Fluoxetine; Ganglia, Spinal; Ion Channel Gating; Male; Neurons; Potassium Channels; Potassium Channels, Tandem Pore Domain; Rats; Riluzole; Temperature | 2018 |
Identification and characterization of two zebrafish Twik related potassium channels, Kcnk2a and Kcnk2b.
Topics: Animals; Antidepressive Agents, Second-Generation; Cells, Cultured; Fluoxetine; HEK293 Cells; Humans; Ion Channel Gating; Membrane Potentials; Neuroprotective Agents; Peptides; Potassium Channels, Tandem Pore Domain; Protein Isoforms; Riluzole; Zebrafish; Zebrafish Proteins | 2018 |